Arbutus Biopharma ABUS
NASDAQ ABUS
$5.14 +0.02 (+0.29%)
As of: Sep 4, 2026 · 12:48 PM EDT

Arbutus Biopharma (ABUS) Non Operating Interest Expenses (2017 - 2026)

Analysis

Arbutus Biopharma (ABUS) Non Operating Interest Expenses (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 93.62 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn 20.27 Mn
10 Arbutus Biopharma 1.01 Bn 921.39 Mn - 18,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 18,000.00
Mar 31, 2026 17,000.00
Dec 31, 2025 18,000.00
Sep 30, 2025 23,000.00
Jun 30, 2025 28,000.00
Mar 31, 2025 28,000.00
Dec 31, 2024 30,000.00
Sep 30, 2024 29,000.00
Jun 30, 2024 34,000.00
Mar 31, 2024 44,000.00
Dec 31, 2023 44,000.00
Sep 30, 2023 46,000.00
Jun 30, 2023 171,000.00
Mar 31, 2023 198,000.00
Dec 31, 2022 309,000.00
Sep 30, 2022 429,000.00
Jun 30, 2022 482,000.00
Mar 31, 2022 506,000.00
Dec 31, 2021 560,000.00
Sep 30, 2021 762,000.00